>
Switch to:

Cara Therapeutics Revenue per Share

: $2.68 (TTM As of Dec. 2020)
View and export this data going back to 2014. Start your Free Trial

Cara Therapeutics's revenue per share for the three months ended in Dec. 2020 was $2.19. Cara Therapeutics's revenue per share for the trailing twelve months (TTM) ended in Dec. 2020 was $2.68.

During the past 12 months, the average Revenue Per Share Growth Rate of Cara Therapeutics was 504.90% per year. During the past 3 years, the average Revenue Per Share Growth Rate was 359.80% per year. During the past 5 years, the average Revenue Per Share Growth Rate was 151.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

NAS:CARA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -82.4   Med: 13.65   Max: 437.6
Current: 359.8

-82.4
437.6

During the past 10 years, Cara Therapeutics's highest 3-Year average Revenue Per Share Growth Rate was 437.60% per year. The lowest was -82.40% per year. And the median was 13.65% per year.

NAS:CARA's 3-Year Revenue Growth Rate is ranked higher than
99% of the 745 Companies
in the Biotechnology industry.

( Industry Median: 1.70 vs. NAS:CARA: 359.80 )

Cara Therapeutics Revenue per Share Historical Data

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cara Therapeutics Annual Data
Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Revenue per Share Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.03 0.38 0.47 2.82

Cara Therapeutics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Revenue per Share Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.17 0.12 0.20 2.19

Cara Therapeutics Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Cara Therapeutics's Revenue Per Share for the fiscal year that ended in Dec. 2020 is calculated as

Revenue Per Share (A: Dec. 2020 )=Revenue (A: Dec. 2020 )/Shares Outstanding (Diluted Average) (A: Dec. 2020 )
=135.082/47.915
=2.82

Cara Therapeutics's Revenue Per Share for the quarter that ended in Dec. 2020 is calculated as

Revenue Per Share (Q: {Q1})=Revenue (Q: Dec. 2020 )/Shares Outstanding (Diluted Average) (Q: Dec. 2020 )
=112.089/51.249
=2.19

Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2020 was 0.173 (Mar. 2020 ) + 0.12 (Jun. 2020 ) + 0.198 (Sep. 2020 ) + 2.187 (Dec. 2020 ) = $2.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cara Therapeutics  (NAS:CARA) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Cara Therapeutics Revenue per Share Related Terms


Cara Therapeutics Revenue per Share Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)